{
    "nct_id": "NCT05756322",
    "official_title": "A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias",
    "inclusion_criteria": "* Male or female subjects greater than 18 years old, inclusive.\n* Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.\n* Patients who are ineligible for standard therapies that are anticipated to result in durable remission or cure, or who have no known therapy options of documented benefit.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* Concomitant chemotherapy, radiation therapy, or immunotherapy.\n* Receiving any other investigational agents concurrently or within 30 days prior to screening.\n* Patient has acute promyelocytic leukaemia or leukemia with active CNS involvement.\n* History of another active malignancy with 2 years prior to study entry, basal cell skin cancer and previous carcinoma in treated curatively.\n* Patient with mental deficits and/or psychiatric history",
    "miscellaneous_criteria": ""
}